Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Tumor immunotherapy is only effective in a fraction of patients due to a low response rate and severe side effects, and these challenges of immunotherapy in clinics can be addressed through induction of immunogenic cell death (ICD). ICD is elicited from many antitumor therapies to release danger ass...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Advanced science Ročník 9; číslo 22; s. e2201734 - n/a
Hlavní autori: Li, Zhilin, Lai, Xiaoqin, Fu, Shiqin, Ren, Long, Cai, Hao, Zhang, Hu, Gu, Zhongwei, Ma, Xuelei, Luo, Kui
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Germany John Wiley & Sons, Inc 01.08.2022
John Wiley and Sons Inc
Predmet:
Antibodies
Antigens
antitumor
Apoptosis
Blood
Cancer therapies
Cytokines
Cytotoxicity
drug delivery system
Efficiency
Heat shock proteins
Humans
Immunogenic Cell Death
Immunologic Factors - pharmacology
Immunotherapy
Immunotherapy - methods
Kinases
Lymphocytes
nanomedicines
Peptides
Photochemotherapy
Physiology
Polyethylene glycol
Review
Reviews
synergic therapy
T-Lymphocytes, Cytotoxic
Tumor Microenvironment
Tumor necrosis factor-TNF
Tumors
synergic therapy
drug delivery system
antitumor
nanomedicines
immunogenic cell death
immunotherapy
ISSN:2198-3844, 2198-3844
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Tumor immunotherapy is only effective in a fraction of patients due to a low response rate and severe side effects, and these challenges of immunotherapy in clinics can be addressed through induction of immunogenic cell death (ICD). ICD is elicited from many antitumor therapies to release danger associated molecular patterns (DAMPs) and tumor‐associated antigens to facilitate maturation of dendritic cells (DCs) and infiltration of cytotoxic T lymphocytes (CTLs). The process can reverse the tumor immunosuppressive microenvironment to improve the sensitivity of immunotherapy. Nanostructure‐based drug delivery systems (NDDSs) are explored to induce ICD by incorporating therapeutic molecules for chemotherapy, photosensitizers (PSs) for photodynamic therapy (PDT), photothermal conversion agents for photothermal therapy (PTT), and radiosensitizers for radiotherapy (RT). These NDDSs can release loaded agents at a right dose in the right place at the right time, resulting in greater effectiveness and lower toxicity. Immunotherapeutic agents can also be combined with these NDDSs to achieve the synergic antitumor effect in a multi‐modality therapeutic approach. In this review, NDDSs are harnessed to load multiple agents to induce ICD by chemotherapy, PDT, PTT, and RT in combination of immunotherapy to promote the therapeutic effect and reduce side effects associated with cancer treatment. This review summarizes the nanostructure‐based drug delivery systems‐based immunogenic cell death (ICD) induction approaches combined with immunotherapy. Engineered and functionalized NDDSs to enhance their delivery efficiency and activate the tumor immune microenvironment for improving immunotherapeutic efficiency are illustrated.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2198-3844
2198-3844
DOI:10.1002/advs.202201734